SECURE 340B Act
July 6, 2026
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
Where This Stands
Currently in_committee. The next step in the legislative lifecycle is Floor Vote.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →The Frame
This legislation could change how hospitals and clinics access discounted prescription drugs, directly impacting the operational costs and service capacity of healthcare providers participating in the 340B program.
Potentially affected actors named in the source documents. Mention is not a position.
340B-covered healthcare entities
These organizations are directly affected as the bill proposes changes to the drug pricing program they utilize.
Pharmaceutical manufacturers
These entities are directly affected by changes to the mandatory discount requirements under the 340B program.
Current stage: in_committee.
Floor Vote.
Background
- The 340B program was established by the Veterans Health Care Act of 1992 to help safety-net providers stretch scarce federal resources. context
Summary
Why It Matters
This legislation could change how hospitals and clinics access discounted prescription drugs, directly impacting the operational costs and service capacity of healthcare providers participating in the 340B program.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What is the 340B program?
What is the current status of the SECURE 340B Act?
News Coverage
Lobbying Activity
340B Health
2026
“The SECURE 340B Act (H.R. 9599); The Tax-Exempt Hospital Transparency Act (H.R.9504); 340B PATIENTS Act (H.R. 4581/S.2372); Community Health Center Drug Pricing Protection Act (H.R. 7391); 2027 OPPS Proposed Rule; Information Collection Request Title: 340B Rebate Model Pilot Program Application, Implementation, and Evaluation, OMB Number 0906-NEW; Manufacturer Demand for Access to in-House Pharmacy Claims Data; Lilly 340B Drug Pricing Denial; HRSA Rebate Model Pilot pending regulation; Pending Senate "Gang of Six" draft 340B legislation; FY27 Appropriations legislation; Pending introduction of updated and expanded Community Health Center Drug Pricing Protection Act.”
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Multi-Committee Referral
The bill was referred to three separate committees, indicating that the proposed changes likely touch on healthcare, tax, and labor/workforce policy areas simultaneously.
Connected Entities
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy50Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools